Insider buying last 90 days
No open-market insider purchases were filed for LEGN in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every LEGN insider filing, plotted on the chart in Gekko.Open LEGN in Gekko
Gekko Brief
AI summaryOct 12 closeThis week's news centers on CARVYKTI, Legend Biotech's cell therapy, and shifting analyst views. Legend presented five-year data showing 50% of patients progression-free after a single infusion and a 69.2% overall survival rate, which lifted the stock 1.10% on 5 October to $18.78, though it fell 4.07% on Tradegate on the presentation day. J.P. Morgan maintained its Hold rating while cutting its target price to $33, while RBC Capital maintained an Outperform rating, reflecting a split in analyst sentiment around the long-term data.
LEGN closed at $17.80, down 4.4%, sitting below both its 50-day average of $19.74 and 200-day average of $22.31, with the 50-day below the 200-day. The stock's three-month return stands at -30.7% and its one-year return at -44.8%, against a 52-week range of $16.24 to $37.50. The GekkoIndex reads 65.8, placing it in the Accumulation zone, while price sits 37.8% below Gekko Fair Value of $28.64.
Legend Biotech's next earnings report is scheduled for 11 November, 30 days away, falling outside a typical 20-trading-day holding window; the prior quarter missed EPS estimates ($0.09 actual versus $0.12 expected) with a flat reaction. One trailblazer holder is noted, though no insider, Congress, or unusual options activity appears in their respective windows. Seasonality over five years shows an average 20-day return of -0.3%, rising in 2 of those years. Analyst consensus across 9 firms (5 buy, 4 hold) carries a target of $46.35, worth noting alongside the current gap to Gekko Fair Value.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Legend Biotech price vs fair value
Close $17.80200-day averageGekko Fair Value $28.64
Legend Biotech quick facts
- Market cap
- $3.29B
- P/E ratio
- —
- Forward P/E
- 27.6
- EPS, TTM
- −$0.52
- Revenue, TTM
- $1.27B
- Profit margin
- -7.2%
- Dividend yield
- —
- Beta
- 0.57
- Volume
- 2.63M avg 2.22M
- 1-year return
- −44.8%
- Typical daily move
- ±4.8%
- Typical 20-day move
- ±8.6%
- 50-day average
- $19.74
- 200-day average
- $22.31
- Next earnings
- Nov 11 before open
- Shares outstanding
- 194.5M
Legend Biotech swing-trade checklist
Legend Biotech scores 3 supportive, 0 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive0 mixed2 headwinds
- Trendheadwind
Below 50 and 200-day
Close $17.80 is below the 50-day ($19.74) and 200-day ($22.31) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexsupportive
65.8, Accumulation
Reading 65.8 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
37.8% below
Price is 37.8% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 30 days
Next report Nov 11, 2026, 30 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−0.3% on average
From this point in the calendar, the next 20 trading days averaged −0.3% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Legend Biotech stock chart and price history
Legend Biotech closed at $17.80 on Oct 12, 2026, −44.8% over the past year, inside a 52-week range of $16.24 to $37.50.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −4.5%
- 3 months
- −30.7%
- 6 months
- +0.6%
- 1 year
- −44.8%
The full LEGN chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open LEGN in Gekko
Follow Legend Biotech through every session
Put LEGN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track LEGN in GekkoFree for 7 days. No credit card required.
About Legend Biotech
Legend Biotech works through its subsidiaries as a biopharmaceutical business focused on cell therapies, with an emphasis on cancer treatment. Its most advanced candidate is ciltacabtagene autoleucel, a CAR-T therapy aimed at multiple myeloma, and this program has become the company's most recognized work. Beyond this, it maintains a wider set of earlier-stage CAR-T candidates aimed at other cancers, including forms of leukemia and several solid tumors.
The company also pursues allogeneic cell therapy approaches, including gamma delta CAR-T and CAR-NK candidates targeting BCMA for multiple myeloma, currently in investigator-led early trials in China. Its commercial and development activity extends across the United States, China, and Europe, and it works with partners on key programs, including a collaboration with Janssen Biotech on its lead therapy and a licensing arrangement with Novartis Pharma covering CAR-T therapies directed at delta-like ligand protein 3.
Legend Biotech was founded in 2014 and is headquartered in Somerset, New Jersey. Its shares trade under the ticker LEGN.
- Sector
- Health technology
- Website
- legendbiotech.com
Legend Biotech GekkoIndex: the smart money zone
Legend Biotech’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 65.8, in the Accumulation zone, up 2.5 points over five sessions.
65.8Accumulation
Up 2.5 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 114 | 0.0% | −2.5% | ||
| Accumulation (current zone) | 265 | −0.8% | −3.2% | ||
| Neutral | 221 | −0.4% | −1.1% | ||
| Distribution | 33 | −0.5% | +0.2% | ||
| Selling | 2 | Too few readings yet | |||
Average LEGN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the LEGN price, zone by zone.Track LEGN in Gekko
Is Legend Biotech stock overvalued? Gekko Fair Value
Legend Biotech trades 37.8% below Gekko Fair Value of $28.64, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Legend Biotech shares are worth, recalculated every trading day.
$28.64
Gekko Fair Value, Oct 10, 2026
37.8% Undervalued
At the end of Aug 2026 the price was 48.3% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open LEGN in Gekko
Legend Biotech insider and Congress trading
No open-market insider purchases were filed for Legend Biotech, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in LEGN were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for LEGN, plotted on the chart in Gekko.Open LEGN in Gekko
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds LEGN.
0added1opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Legend Biotech earnings: next date and track record
Legend Biotech reports on Nov 11, 2026, before the open (30 days away), and beat the EPS estimate in 3 of its last 8 reports.
Next earnings report
Nov 11, 2026
Expected before the open, 30 days away
- EPS estimate
- $0.01
- Revenue estimate
- $359.1M
3 of 8reports beat the EPS estimate
±6.2%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 11, 2026 AI summary
- What they said
- Legend Biotech reported strong Q2 2026 results with CARVYKTI generating $657M in worldwide net trade sales, up 50% year-over-year (32% US, 128% ex-US). The company achieved adjusted net income of $63M in Q2. CARVYKTI now has 150+ authorized treatment centers across 348 global sites in 19 markets, with growing adoption in earlier lines of therapy. Balance sheet was strengthened via a $212M equity offering, ending Q2 with ~$965M cash.
- Guidance
- Management expects to maintain adjusted net income profitability through the second half of 2026. No specific revenue targets were provided, but continued CARVYKTI growth is anticipated from earlier line adoption and geographic expansion.
- Risks flagged
- Leadership transition (interim CEO in place); collaboration constraints with J&J limiting disclosure/decision-making around certain BCMA programs; competitive pressure from bispecifics (e.g., TEC/TAL) and sequencing dynamics; potential gross margin headwinds from a growing outpatient mix; tax provision and international tax/treatment uncertainties (China tax impact); outstanding loan repayment and related cash flow impacts; development and regulatory risks for in vivo and other pipeline programs, and challenges expanding in vivo into solid tumors and autoimmune indications.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 11, 2026 | $0.09 est $0.12 | $387.5M est $356.0M | 0.0% |
| May 12, 2026 | −$0.15 est $0.01 | $305.1M est $306.5M | +12.1% |
| Mar 10, 2026 | −$0.16 est −$0.19 | $306.3M est $307.8M | +5.9% |
| Nov 12, 2025 | −$0.11 est −$0.13 | $272.3M est $309.5M | −3.2% |
| Aug 11, 2025 | −$0.34 est −$0.22 | $256.0M est $278.2M | 0.0% |
| May 13, 2025 | −$0.54 est −$0.34 | $195.1M est $218.0M | −14.1% |
| Mar 11, 2025 | $0.14 est −$0.38 | $186.5M est $191.3M | +12.4% |
| Nov 12, 2024 | −$0.68 est −$0.42 | — | −1.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Legend Biotech stock forecast and analyst price targets
Analysts’ average 12-month price target for Legend Biotech is $46.35, +160.4% from the last close, from 9 firms rating the stock in the last 90 days.
$46.35consensus 12-month target, +160.4% from the last close
Now $17.80Avg $46.35
Low $24High $74
Each firm’s latest rating in the last 90 days: 9 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 9 | J.P. Morgan | $33 | +85.4% |
| Oct 8 | RBC Capital | $56 | +214.6% |
| Oct 2 | UBS | $24 | +34.8% |
| Sep 30 | H.C. Wainwright | $65 | +265.2% |
| Sep 28 | H.C. Wainwright | $65 | +265.2% |
−3.2%average 20-day move after past Accumulation readings
−0.3%average move over the next 20 trading days in the last 5 years
±4.8%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Legend Biotech seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Legend Biotech averaged −0.3% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −2.9% | 3 of 5 |
| Next 10 trading days | +0.3% | 2 of 5 |
| Next 15 trading days | +2.4% | 2 of 5 |
| Next 20 trading days | −0.3% | 2 of 5 |
| Next 30 trading days | −4.1% | 1 of 5 |
For scale, LEGN’s typical 20-trading-day move in either direction is about 8.6%.
Legend Biotech market cap and key statistics
Legend Biotech’s market cap is $3.29B and revenue of $1.27B over the last twelve months.
Valuation
- Market cap
- $3.29B
- Forward P/E
- 27.6
- EPS, TTM
- −$0.52
- Gekko Fair Value
- $28.64
Trading
- Volume
- 2.63M
- Avg volume, 20 days
- 2.22M
- 52-week high
- $37.50
- 52-week low
- $16.24
- Shares outstanding
- 194.5M
Financials
- Revenue, TTM
- $1.27B
- Profit margin
- -7.2%
- Return on equity
- -8.1%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.57
- Typical daily move
- ±4.8%
- Typical 20-day move
- ±8.6%
Legend Biotech stock news this week
Coverage of Legend Biotech this week reads neutral: 2 positive, 2 neutral and 2 negative headlines.
- Net income before discontinued operations of Legend Biotech Corp. Sponsored ADR – HAN:9LBTradingView, Oct 11
- J.P. Morgan Maintains Legend Biotech(LEGN.US) With Hold Rating, Cuts Target Price to $33Moomoo, Oct 9
- Legend Biotech Is Maintained at Outperform by RBC CapitalMoomoo, Oct 9
- Legend Biotech Corp (HAM:9LB) Stock Forecast, Price Targets and Analysts PredictionsGuruFocus, Oct 7
- Legend Biotech presents CARVYKTI data and LEGN stock fell 4.07 percentAD HOC NEWS, Oct 7
- Legend Biotech stock gained 1.10 percent on October 5AD HOC NEWS, Oct 6
Legend Biotech stock FAQ
What is Legend Biotech’s market cap?
Legend Biotech’s market cap is $3.29B at the Oct 12, 2026 close of $17.80, with 194.5M shares outstanding.
What is the Legend Biotech stock forecast?
The consensus analyst 12-month price target for Legend Biotech is $46.35, +160.4% from the last close. Of the 9 firms that rated the stock in the last 90 days, 5 rate it a buy, 4 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Legend Biotech stock overvalued or undervalued?
On Gekko’s estimate Legend Biotech is undervalued: the Oct 12, 2026 close of $17.80 is 37.8% below Gekko Fair Value of $28.64. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Legend Biotech report earnings next?
Legend Biotech is expected to report on Nov 11, 2026, before the market opens (30 days away). Analysts expect earnings of $0.01 per share on revenue of $359.1M. Legend Biotech beat the earnings estimate in 3 of its last 8 reports, moving 6.2% on average across the report.
What is Legend Biotech’s 52-week high and low?
Legend Biotech’s 52-week high is $37.50 and its 52-week low is $16.24; it closed at $17.80 on Oct 12, 2026, −44.8% over the past year. Over the last five years the shares peaked at $77.32 on Jul 21, 2023.
Is Legend Biotech stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and earnings risk) and 2 as headwinds (trend and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Legend Biotech the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.